Nano24 is a clinical-stage company at the forefront of developing the next generation of steroids. Their innovative therapy focuses on CD24-enriched exosomes to target the hyper-activation of the immune system. Founded in 2020 by Prof. Nadir Arber and Dr. Shiran Shapira, Nano24 Ltd. aims to commercialize cutting-edge technologies resulting from extensive applied and clinical research undertaken in their lab.

By harnessing advanced science and technology, Nano24 recruits global experts to develop a robust therapy for cytokine storm syndrome, a condition with no effective treatment currently available. The company is dedicated to designing the future of medicine with a focus on simplicity, out-of-the-box thinking, and precision.

Nano24 recognizes the urgent need for medical advancements, as acute respiratory distress syndrome (ARDS) affects millions of patients each year, with high mortality rates and no effective treatment options. With their game-changing approach, Nano24 is poised to revolutionize the field and provide hope to those in need.